Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects

Dement Geriatr Cogn Disord. 2011;31(6):413-6. doi: 10.1159/000329763. Epub 2011 Jul 13.


Background/aims: Detection and differentiation of neurodegenerative dementias, such as dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), with blood-based biomarkers would facilitate diagnosis and treatment.

Methods: By use of a commercially available ELISA kit, we measured α-synuclein levels in the serum of 40 DLB patients and controls, and of 80 AD patients.

Results: We found significantly reduced α-synuclein serum levels in DLB compared to both AD (p = 0.006) and control subjects (p = 0.001), reaching an area under the curve of >0.70.

Conclusion: Although these results do not justify a definition of serum α-synuclein as a potential single biomarker, results may contribute to a multimarker strategy in DLB diagnosis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / blood*
  • Area Under Curve
  • Biomarkers / blood
  • Data Interpretation, Statistical
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Lewy Body Disease / blood*
  • Male
  • Neuropsychological Tests
  • ROC Curve
  • Reproducibility of Results
  • alpha-Synuclein / blood*


  • Biomarkers
  • alpha-Synuclein